Literature DB >> 21302010

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.

Martin Bergstrand1, Andrew C Hooker, Johan E Wallin, Mats O Karlsson.   

Abstract

Informative diagnostic tools are vital to the development of useful mixed-effects models. The Visual Predictive Check (VPC) is a popular tool for evaluating the performance of population PK and PKPD models. Ideally, a VPC will diagnose both the fixed and random effects in a mixed-effects model. In many cases, this can be done by comparing different percentiles of the observed data to percentiles of simulated data, generally grouped together within bins of an independent variable. However, the diagnostic value of a VPC can be hampered by binning across a large variability in dose and/or influential covariates. VPCs can also be misleading if applied to data following adaptive designs such as dose adjustments. The prediction-corrected VPC (pcVPC) offers a solution to these problems while retaining the visual interpretation of the traditional VPC. In a pcVPC, the variability coming from binning across independent variables is removed by normalizing the observed and simulated dependent variable based on the typical population prediction for the median independent variable in the bin. The principal benefit with the pcVPC has been explored by application to both simulated and real examples of PK and PKPD models. The investigated examples demonstrate that pcVPCs have an enhanced ability to diagnose model misspecification especially with respect to random effects models in a range of situations. The pcVPC was in contrast to traditional VPCs shown to be readily applicable to data from studies with a priori and/or a posteriori dose adaptations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21302010      PMCID: PMC3085712          DOI: 10.1208/s12248-011-9255-z

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  12 in total

1.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Comput Methods Programs Biomed       Date:  1999-01       Impact factor: 5.428

2.  Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming.

Authors:  Lars Lindbom; Jakob Ribbing; E Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2004-08       Impact factor: 5.428

3.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

Review 4.  Diagnosing model diagnostics.

Authors:  M O Karlsson; R M Savic
Journal:  Clin Pharmacol Ther       Date:  2007-07       Impact factor: 6.875

5.  Handling data below the limit of quantification in mixed effect models.

Authors:  Martin Bergstrand; Mats O Karlsson
Journal:  AAPS J       Date:  2009-05-19       Impact factor: 4.009

6.  Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia.

Authors:  L E Friberg; R de Greef; T Kerbusch; M O Karlsson
Journal:  Clin Pharmacol Ther       Date:  2009-04-22       Impact factor: 6.875

7.  Approaches to handling pharmacodynamic baseline responses.

Authors:  Chantaratsamon Dansirikul; Hanna E Silber; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-04-30       Impact factor: 2.745

Review 8.  The future of drug development: advancing clinical trial design.

Authors:  John Orloff; Frank Douglas; Jose Pinheiro; Susan Levinson; Michael Branson; Pravin Chaturvedi; Ene Ette; Paul Gallo; Gigi Hirsch; Cyrus Mehta; Nitin Patel; Sameer Sabir; Stacy Springs; Donald Stanski; Matthias R Evers; Edd Fleming; Navjot Singh; Tony Tramontin; Howard Golub
Journal:  Nat Rev Drug Discov       Date:  2009-10-09       Impact factor: 84.694

9.  Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool.

Authors:  Johan E Wallin; Lena E Friberg; Anders Fasth; Christine E Staatz
Journal:  Ther Drug Monit       Date:  2009-08       Impact factor: 3.681

10.  Extensions to the visual predictive check to facilitate model performance evaluation.

Authors:  Teun M Post; Jan I Freijer; Bart A Ploeger; Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-01-16       Impact factor: 2.745

View more
  520 in total

1.  Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.

Authors:  Christelle Rodrigues; Catherine Chiron; Elisabeth Rey; Olivier Dulac; Emmanuelle Comets; Gérard Pons; Vincent Jullien
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

2.  Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

Authors:  Huixin Yu; Neeltje Steeghs; Jacqueline S L Kloth; Djoeke de Wit; J G Coen van Hasselt; Nielka P van Erp; Jos H Beijnen; Jan H M Schellens; Ron H J Mathijssen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

3.  Automatic data binning for improved visual diagnosis of pharmacometric models.

Authors:  Marc Lavielle; Kevin Bleakley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-26       Impact factor: 2.745

4.  Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.

Authors:  Lena E Friberg; Patanjali Ravva; Mats O Karlsson; Ping Liu
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

5.  A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations.

Authors:  Martin Bergstrand; Erik Söderlind; Ulf G Eriksson; Werner Weitschies; Mats O Karlsson
Journal:  Pharm Res       Date:  2011-09-23       Impact factor: 4.200

6.  A semi-mechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations.

Authors:  Martin Bergstrand; Erik Söderlind; Ulf G Eriksson; Werner Weitschies; Mats O Karlsson
Journal:  Pharm Res       Date:  2011-09-27       Impact factor: 4.200

7.  Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.

Authors:  Cindy J Bednasz; Charles S Venuto; Qing Ma; Eric S Daar; Paul E Sax; Margaret A Fischl; Ann C Collier; Kimberly Y Smith; Camlin Tierney; Edward P Acosta; Donald E Mager; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

8.  Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment.

Authors:  Vibeke Klastrup; Anders Thorsted; Merete Storgaard; Steffen Christensen; Lena E Friberg; Kristina Öbrink-Hansen
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

9.  A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators.

Authors:  Ida Robertsen; Jean Debord; Anders Åsberg; Pierre Marquet; Jean-Baptiste Woillard
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

10.  Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.

Authors:  Jeannine S McCune; Meagan J Bemer; Jeffrey S Barrett; K Scott Baker; Alan S Gamis; Nicholas H G Holford
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.